Metabolic reprograming of anti-tumor immunity

Current Opinion in Immunology

Volumn 46, Issue , 2017, Pages 14-22

  Sukumar, Madhusudhanan ^a   Kishton, Rigel J ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ACTIVITY; CELL DESTRUCTION; CELL METABOLISM; HUMAN; IMMUNOTHERAPY; MODULATION; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR RESISTANCE; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; ENERGY METABOLISM; IMMUNITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MITOCHONDRION; NEOPLASM; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; CELL DIFFERENTIATION; ENERGY METABOLISM; HUMANS; IMMUNITY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MITOCHONDRIA; NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 85017464655     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2017.03.011     Document Type: Review

References (61)

1. 1 Mehlen, P., Puisieux, A., Metastasis: a question of life or death. Nat Rev Cancer 6 (2006), 449–458.
2. 2 Cardoso, F., et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol 13 (2002), 197–207.
3. 3 Spaans, J.N., Goss, G.D., Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. Front Oncol, 4, 2014, 190.
4. 4• Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68 An update on recent developments in the field of adoptive immunotherapy using conventional T cell receptors to treat melanoma and other common epithelial cancers.
5. 5 Robbins, P.F., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29 (2011), 917–924.
6. 6 Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
7. 7 Kochenderfer, J.N., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
8. 8 Grupp, S.A., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518.
9. 9 Rosenberg, S.A., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17 (2011), 4550–4557.
10. 10 Tran, E., et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375 (2016), 2255–2262.
11. 11•• Chang, C.H., Pearce, E.L., Emerging concepts of T cell metabolism as a target of immunotherapy. Nat Immunol 17 (2016), 364–368 This comprehensive review covers the basic metabolic pathways in T cells, and discusses about the relationship between metabolism and T cell function and longevity and covers discussions in which T cells might be manipulated by the reprogramming of metabolic pathways for therapeutic purposes.
12. 12 Gattinoni, L., et al. A human memory T cell subset with stem cell-like properties. Nat Med 17 (2011), 1290–1297.
13. 13 Pearce, E.L., et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460 (2009), 103–107.
14. 14 Michalek, R.D., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 186 (2011), 3299–3303.
15. 15 Sukumar, M., Gattinoni, L., The short and sweet of T-cell therapy: restraining glycolysis enhances the formation of immunological memory and antitumor immune responses. Oncoimmunology, 3, 2016, e27573.
16. 16 Rosenberg, S.A., et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8 (2008), 299–308.
17. 17 Klebanoff, C.A., et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 102 (2005), 9571–9576.
18. 18 Gattinoni, L., et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15 (2009), 808–813.
19. 19 Muranski, P., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112 (2008), 362–373.
20. 20•• Sukumar, M., et al. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab 23 (2016), 63–76 This study has shown that the level of mitochondrial membrane potential (ΔΨm) in T cells and HSC may regulate the stemness, differentiation and functionality, with low-ΔΨm is associated with enhanced stemness (TSCM and LT-HSC), while high-ΔΨm is associated with increased differentiation, cytokine production, ROS and oxidative stress.
21. 21 Luckey, C.J., et al. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci U S A 103 (2006), 3304–3309.
22. 22 Vannini, N., et al. Specification of haematopoietic stem cell fate via modulation of mitochondrial activity. Nat Commun, 7, 2016, 13125.
23. 23 Bertolo, A., et al. Oxidative status predicts quality in human mesenchymal stem cells. Stem Cell Res Ther, 8, 2017, 3.
24. 24 Tothova, Z., et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128 (2007), 325–339.
25. 25 Ito, K., et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431 (2004), 997–1002.
26. 26 Sena, L.A., et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38 (2013), 225–236.
27. 27 Weinberg, S.E., Sena, L.A., Chandel, N.S., Mitochondria in the regulation of innate and adaptive immunity. Immunity 42 (2015), 406–417.
28. 28 Pollizzi, K.N., et al. Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation. Nat Immunol 17 (2016), 704–711.
29. 29 Verbist, K.C., et al. Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature 532 (2016), 389–393.
30. 30 Scholz, G., et al. Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells. EBioMedicine 4 (2016), 50–61.
31. 31 Yang, K., et al. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat Immunol 12 (2011), 888–897.
32. 32 Araki, K., et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460 (2009), 108–112.
33. 33 Pollizzi, K.N., et al. mTORC1 and mTORC2 selectively regulate CD8(+) T cell differentiation. J Clin Invest 125 (2015), 2090–2108.
34. 34 Shrestha, S., et al. Tsc1 promotes the differentiation of memory CD8+ T cells via orchestrating the transcriptional and metabolic programs. Proc Natl Acad Sci U S A 111 (2014), 14858–14863.
35. 35 Rao, R.R., et al. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 32 (2010), 67–78.
36. 36• O'Neill, L.A., Kishton, R.J., Rathmell, J., A guide to immunometabolism for immunologists. Nat Rev Immunol 16 (2016), 553–565 An elegant review that discusses the recent advances in the field of immunometabolism. This review covers the complex interplay between metabolic reprogramming and immunity, providing a better understanding of the immune system in health and disease.
37. 37 Macintyre, A.N., et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab 20 (2014), 61–72.
38. 38 Gerriets, V.A., et al. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest 125 (2015), 194–207.
39. 39 Wang, R., et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35 (2011), 871–882.
40. 40 van der Windt, G.J., et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36 (2012), 68–78.
41. 41 Sukumar, M., et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 123 (2013), 4479–4488.
42. 42• Patsoukis, N., et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun, 6, 2015, 6692 This study provided the first evidence that upon PD-1 ligation, activated T cells had increased expression of CPT1a, fatty acid oxidation and are unable to engage in glycolysis. This study suggested that the enhancement of FAO may provide a mechanism for the longevity of T cells receiving PD-1 signals in patients with cancer.
43. 43 Peng, M., et al. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 354 (2016), 481–484.
44. 44 Chang, C.H., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153 (2013), 1239–1251.
45. 45 Crompton, J.G., et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res 75 (2015), 296–305.
46. 46 Yang, W., et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 531 (2016), 651–655.
47. 47 Kawalekar, O.U., et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44 (2016), 380–390.
48. 48•• Buck, M.D., et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166 (2016), 63–76 This study demonstrated that mitochondrial ultrastructure controls T cell fate and metabolism. They showed that memory T cells have fused mitochondria and favored oxidative phosphorylation and FAO in memory T cells. In contrast, mitochondrial fission in effector cells leads to cristae expansion and promoted aerobic glycolysis. This is the first study suggesting that enforcing fusion can improve T cell based adoptive immunotherapy against tumors.
49. 49 Geiger, R., et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167 (2016), 829–842.
50. 50•• Ho, P.C., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162 (2015), 1217–1228 Together with Ref. [44], this paper describes the Warburg metabolism enables tumor cells to restrict glucose availability to T cells, suppressing anti-tumor immunity. Chang CH et al., demonstrated that checkpoint blockade antibodies against CTLA-4, PD-1, and PD-L1, restore glucose in tumor microenvironment, permitting T cell glycolysis and IFN-γ production. HO PC et al. shows that phosphoenolpyruvate carboxykinase 1 (PCK1) overexpression in T cells increased effector function that results in restricted tumor growth.
51. 51 Doedens, A.L., et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol 14 (2013), 1173–1182.
52. 52• Clever, D., et al. Oxygen sensing by T cells establishes an immunologically tolerant metastatic niche. Cell, 166, 2016 1117–1131.e14 This study demonstrated that inhibition of PHD Proteins in CD4+ T cells results in increased HIF1 activity, elevated aerobic glycolysis and heightened effector differentiation. Furthermore, this study highlighted that pharmacological inhibition of PHD proteins in CD4+ T cells can improve T cell effector function and adoptive cell transfer immunotherapy against B16 melanoma.
53. 53 Eil, R., et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537 (2016), 539–543.
54. 54 Bengsch, B., et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity 45 (2016), 358–373.
55. 55•• Scharping, N.E., et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45 (2016), 374–388 This study demonstrated that tumor infiltrating lymphocytes within mouse tumors display reduced levels of mitochondrial mass and metabolism. They further provided evidence that overexpression of PGC-1a in T cells increased mitochondrial biogenesis and effector function of T cells and anti-tumor immunity.
56. + T cell differentiation. By showing that glycolytic metabolism does not hinder differentiation of memory CD8+ T cells, this study proposes an interesting model where increased spare respiratory capacity and a reliance on OXPHOS are not essential for memory CD8+ T cells.
57. 57 Piret, J.P., et al. Is HIF-1alpha a pro- or an anti-apoptotic protein?. Biochem Pharmacol 64 (2002), 889–892.
58. 58 Makino, Y., et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol 171 (2003), 6534–6540.
59. 59 Kerkar, S.P., Restifo, N.P., Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 72 (2012), 3125–3130.
60. 60 Zhao, E., et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 17 (2016), 95–103.
61. 61 Cui, W., et al. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 35 (2011), 792–805.